Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 8/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700140 | 0.94 | RORC (0.45) | RORCBRD4PRKCQPRKCDCNR2 | |
| SCHEMBL1700047 | 0.83 | CA1 (0.51) | RORCBRD4CNR2CA2CA1 | |
| SCHEMBL1700200 | 0.78 | MAPT (0.53) | RORC | |
| SCHEMBL1700398 | 0.77 | BRD4 (0.48) | RORCBRD4CNR2CA2CA1 | |
| SCHEMBL1700346 | 0.76 | CA2 (0.51) | RORCBRD4CNR2CA2CA1 | |
| SCHEMBL1700195 | 0.76 | RORC (0.45) | RORCBRD4CNR2CA2CA1 | |
| SCHEMBL1700150 | 0.76 | CNR2 (0.51) | RORCBRD4PRKCQPRKCDCNR2 | |
| SCHEMBL1497199 | 0.75 | CA2 (0.52) | CA2CA1CA9PTGS1PTGS2 | |
| SCHEMBL1700296 | 0.75 | BRD4 (0.43) | BRD4PRKCQPRKCDCNR2PTGS1 | |
| SCHEMBL1808959 | 0.75 | RORC (0.51) | RORCBRD4CNR2CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376480-A2 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010065865-A2 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |